WO2018141313A3 - Uses of fgf-4 compounds - Google Patents

Uses of fgf-4 compounds Download PDF

Info

Publication number
WO2018141313A3
WO2018141313A3 PCT/CN2018/083256 CN2018083256W WO2018141313A3 WO 2018141313 A3 WO2018141313 A3 WO 2018141313A3 CN 2018083256 W CN2018083256 W CN 2018083256W WO 2018141313 A3 WO2018141313 A3 WO 2018141313A3
Authority
WO
WIPO (PCT)
Prior art keywords
fgf
compounds
prevention
treatment
specifically
Prior art date
Application number
PCT/CN2018/083256
Other languages
French (fr)
Other versions
WO2018141313A2 (en
WO2018141313A9 (en
Inventor
Hao Wu
Zhe Wang
Dan HAN
Fang Zhang
Xiaoli Chen
Rasmus Joergensen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to PCT/CN2018/083256 priority Critical patent/WO2018141313A2/en
Publication of WO2018141313A2 publication Critical patent/WO2018141313A2/en
Publication of WO2018141313A9 publication Critical patent/WO2018141313A9/en
Publication of WO2018141313A3 publication Critical patent/WO2018141313A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are uses of FGF-4 compounds. More specifically, provided are uses of FGF-4 compounds in the prevention and/or treatment of metabolic disorders.
PCT/CN2018/083256 2018-04-17 2018-04-17 Uses of fgf-4 compounds WO2018141313A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/083256 WO2018141313A2 (en) 2018-04-17 2018-04-17 Uses of fgf-4 compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/083256 WO2018141313A2 (en) 2018-04-17 2018-04-17 Uses of fgf-4 compounds

Publications (3)

Publication Number Publication Date
WO2018141313A2 WO2018141313A2 (en) 2018-08-09
WO2018141313A9 WO2018141313A9 (en) 2018-09-07
WO2018141313A3 true WO2018141313A3 (en) 2019-02-21

Family

ID=63039362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/083256 WO2018141313A2 (en) 2018-04-17 2018-04-17 Uses of fgf-4 compounds

Country Status (1)

Country Link
WO (1) WO2018141313A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111944035B (en) * 2019-05-14 2022-08-12 温州医科大学 FGF4 and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012053A2 (en) * 2001-08-01 2003-02-13 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis
WO2011158125A2 (en) * 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
CN102971001A (en) * 2009-08-14 2013-03-13 阿勒根公司 Methods of treating cancer using growth factor retargeted endopeptidases
KR101490017B1 (en) * 2013-03-14 2015-02-09 건국대학교 산학협력단 Medium Composition for Establishing Novel Epiblast Stem Cell and Method for Establishing Novel Epiblast Stem Cell Using Thereof
WO2015171928A2 (en) * 2014-05-07 2015-11-12 Joslin Diabetes Center, Inc. Methods and compositions for induction of ucp1 expression

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012053A2 (en) * 2001-08-01 2003-02-13 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis
CN102971001A (en) * 2009-08-14 2013-03-13 阿勒根公司 Methods of treating cancer using growth factor retargeted endopeptidases
WO2011158125A2 (en) * 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
KR101490017B1 (en) * 2013-03-14 2015-02-09 건국대학교 산학협력단 Medium Composition for Establishing Novel Epiblast Stem Cell and Method for Establishing Novel Epiblast Stem Cell Using Thereof
WO2015171928A2 (en) * 2014-05-07 2015-11-12 Joslin Diabetes Center, Inc. Methods and compositions for induction of ucp1 expression

Also Published As

Publication number Publication date
WO2018141313A2 (en) 2018-08-09
WO2018141313A9 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
WO2019227085A8 (en) Designed bacterial compositions and uses thereof
WO2017218949A3 (en) Peptidomimetic macrocycles and uses thereof
IL291460A (en) Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2016086210A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
WO2018019823A8 (en) Administration and dosage of diaminophenothiazines
WO2021022163A3 (en) Compounds and uses thereof
WO2017156495A8 (en) Compounds and methods for modulating bruton's tyrosine kinase
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
WO2017106364A3 (en) Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
IL291445A (en) Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
EP3579827A4 (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
WO2019209962A8 (en) Compounds and uses thereof
CN113038946A8 (en) Treatment of autism and autism spectrum disorders with biotin compositions
WO2016127123A3 (en) Compounds and methods for preventing or treating sensory hair cell death
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2019026065A3 (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
WO2016130581A8 (en) Combination cancer therapy
WO2016181220A3 (en) Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof
WO2019071021A3 (en) Immunomodulatory oligosaccharides
WO2018141313A3 (en) Uses of fgf-4 compounds
WO2020154571A8 (en) Compounds and uses thereof
WO2019209948A8 (en) Compounds and uses thereof
EP4233890A3 (en) Peptides for treatment and prevention of diabetes and associated disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18747641

Country of ref document: EP

Kind code of ref document: A2